Quick Answer
Metagenomi Therapeutics, Inc. reported Stockholders Equity of $158.60 million for the year ending 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -32.5% in Stockholders Equity from 2024 to 2025.
- This data is from Metagenomi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$90.01 million | Q2 2023: -$102.54 million | Q3 2023: -$119.0 thousand | Q1 2024: $275.63 million | Q2 2024: $269.42 million | Q3 2024: $255.77 million | Q1 2025: $212.66 million | Q2 2025: $195.83 million | Q3 2025: $178.45 million.
- Over the full 4 years of available data (2022 to 2025), Metagenomi Therapeutics, Inc.'s Stockholders Equity has grown by 313.1%.
- Historical annual values: Fiscal year 2025: $158.60 million | Fiscal year 2024: $234.86 million | Fiscal year 2023: -$135.58 million | Fiscal year 2022: -$74.43 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: